Table 3

Overview of commonly reported serious adverse events

Serious adverse eventsTocilizumab exposure (N=417; 407.0 PYs)
Patients, n (%) Events, nRate/100 PYs
Serious infections55 (13.2)7418.2
 Bacterial pneumonia10 (2.4)122.9
 Gastroenteritis8 (1.9)92.2
 Bronchitis4 (1.0)61.5
 Cellulitis3 (0.7)30.7
 Sepsis3 (0.7)30.7
 Herpes zoster3 (0.7)30.7
 Influenza3 (0.7)30.7
Pneumocystis jirovecii pneumonia2 (0.5)20.5
 Varicella2 (0.5)20.5
Macrophage activation syndrome24 (5.8)266.4
Serious infusion-related reactions8 (1.9)143.4
  • PYs, patient-years.